ANXV is under clinical development by Annexin Pharmaceuticals and currently in Phase II for Retinal Vein Occlusion. According to GlobalData, Phase II drugs for Retinal Vein Occlusion have a 41% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ANXV’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ANXV overview

ANXV (AP-01) is under development for the treatment of peripheral occlusive arterial disease, atherosclerosis, sickle cell disease, sepsis, coronavirus disease 2019 (COVID-19) pneumonia and central renal vein occlusion (CRVO). It is administered through intravenous route. It acts by targeting phospholipase A2 and protein kinase C. The drug candidate is a recombinant form of protein annexin A5. It was also under development for the treatment of viral hemorrhagic fevers (VHFs).

Annexin Pharmaceuticals overview

Annexin Pharmaceuticals (Annexin) is a biotechnology company. It develops of new therapeutic approaches for cardiovascular diseases with vascular damage and inflammation. The company’s lead product candidate ANXV, a human recombinant protein; and Annexin A5, developed to protect and repair the blood vessels. Its Annexin A5 builds a ‘shield’ around the repaired cells and works as an anti-inflammatory agent. The company’s products are also used for the treatment of peripheral arterial occlusive disease; stroke, orphan vascular diseases such as central retinal vein occlusion and sickle cell disease; myocardial infarction and other viral diseases. It also conducts in vitro and in vivo studies against inflammation and rupture of atherosclerotic plaques. Annexin is headquartered in Stockholm, Sweden.

For a complete picture of ANXV’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.